Abstract | BACKGROUND: PROCEDURES: A retrospective chart review of pediatric patients treated with cisplatin or carboplatin between 2000 and 2012 was conducted. The incidence of ototoxicity was determined based on the American-Speech-Language-Hearing Association (ASHA) criteria and severity was based on the Chang classification. RESULTS: Four hundred and sixty-six patients received platinum-based chemotherapy. Patients were excluded due to congenital hearing loss (n = 1) and insufficient data for calculating the platinum dose (n = 24) or for assessing ototoxicity (n = 135). Three hundred and six patients were included in the analysis. Post- chemotherapy ototoxicity was detected in 148 (48%) patients, and clinically-significant ototoxicity was present in 91 (30%). In addition, based on the ASHA criteria, 48% of patients (97/204) with long-term follow-up had further deterioration of their hearing after completion of treatment. CONCLUSIONS:
|
Authors | Emilia Peleva, Nader Emami, Mohammad Alzahrani, Aren Bezdjian, Joshua Gurberg, Anne-Sophie Carret, Sam J Daniel |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 61
Issue 11
Pg. 2012-7
(Nov 2014)
ISSN: 1545-5017 [Electronic] United States |
PMID | 24976616
(Publication Type: Journal Article)
|
Copyright | © 2014 Wiley Periodicals, Inc. |
Chemical References |
- Antineoplastic Agents
- Carboplatin
- Cisplatin
|
Topics |
- Adolescent
- Adult
- Antineoplastic Agents
(adverse effects)
- Carboplatin
(adverse effects)
- Child
- Child, Preschool
- Cisplatin
(adverse effects)
- Female
- Hearing Loss
(chemically induced)
- Humans
- Infant
- Logistic Models
- Male
- Retrospective Studies
|